| Robert Todd Campbell, MD | |
|
2980 Squalicum Pkwy, Bellingham, WA 98225-1880 | |
| (360) 647-3377 | |
| (360) 752-3214 |
| Full Name | Robert Todd Campbell |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 27 Years |
| Location | 2980 Squalicum Pkwy, Bellingham, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083637599 | NPI | - | NPPES |
| 50088342 | Other | WA | MEDICARE RR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD00040943 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bellingham, WA | Hospital |
| Cascade Valley Hospital | Arlington, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bellingham Anesthesia Associates Ps | 6406755990 | 54 |
News Archive
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
Most patients with an abrupt kidney injury that does not get better do not see a kidney specialist within a year, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.
› Verified 5 days ago
| Entity Name | Bellingham Anesthesia Associates Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609893460 PECOS PAC ID: 6406755990 Enrollment ID: O20040105000120 |
News Archive
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
Most patients with an abrupt kidney injury that does not get better do not see a kidney specialist within a year, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Todd Campbell, MD 2980 Squalicum Pkwy, Bellingham, WA 98225-1880 Ph: (360) 647-3377 | Robert Todd Campbell, MD 2980 Squalicum Pkwy, Bellingham, WA 98225-1880 Ph: (360) 647-3377 |
News Archive
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
Most patients with an abrupt kidney injury that does not get better do not see a kidney specialist within a year, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.
› Verified 5 days ago
John Erik Schroeter, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 2980 Squalicum Pkwy, Suite 105, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 | |
Robert Kahn, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2901 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-734-5400 | |
Arjun Chenna Reddy, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 909 Squalicum Way Ste 102, Bellingham, WA 98225 Phone: 606-473-3773 | |
Dr. Gregory Carl Sund, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 2980 Squalicum Pkwy, Suite 304, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 | |
Dr. John Edwin Morrison, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 909 Squalicum Way Ste 102, Bellingham, WA 98225 Phone: 360-647-3377 | |
Dr. Nishan Bingham, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 909 Squalicum Way Ste 102, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 |